Year 2021 / Volume 113 / Number 10
Letter
Tofacitinib, a useful option for the treatment of pyoderma gangrenosum in an ulcerative colitis patient

733-734

DOI: 10.17235/reed.2021.7977/2021

Pablo Salmón Olavarría, Saioa Rubio Iturria, Óscar Nantes Castillejo,

Abstract
Pyoderma gangrenosum (PG) is a difficult-to-manage ulcero-necrotizing dermatosis associated with inflammatory bowel disease (IBD). In this article, we report a refractory PG in a patient with severe ulcerative colitis (UC) that responded to tofacitinib 10 mg/12 h.
Share Button
New comment
Comments
No comments for this article
References
1. Plumptre I, Knabel D, Tomecki K. Pyoderma gangrenosum: a review for the gastroenterologist. Inflamm Bowel Dis 2018;24:2510-7. DOI: 10.1093/ibd/izy174
2. Kochar B, Herfarth N, Mamie C, et al. Tofacitinib for the Treatment of Pyoderma Gangrenosum. Clin Gastroenterol Hepatol 2019;17(5):991-3.
3. Gregory MH, Ciorba MA, Deepak P, et al. Successful Treatment of Pyoderma Gangrenosum with Concomitant Tofacitinib and Infliximab. Inflamm Bowel Dis 2019;25(7):e87-8. DOI: 10.1093/ibd/izz015
4. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2017;376(18):1723-36.
Related articles

Letter

Broadening perspectives in the treatment of chronic pouchitis

DOI: 10.17235/reed.2024.10865/2024

Letter

Tofacitinib-induced eosinophilia

DOI: 10.17235/reed.2023.9831/2023

Letter

Lymphocytic colitis with macroscopic findings

DOI: 10.17235/reed.2023.9497/2023

Letter

Hepatosplenic T-cell lymphoma and inflammatory bowel disease

DOI: 10.17235/reed.2023.9472/2023

Letter

Perianal Paget’s disease

DOI: 10.17235/reed.2022.9304/2022

Letter

Chinese dragon sign of ulcerative colitis

DOI: 10.17235/reed.2022.9154/2022

Letter

Ulcerative colitis exacerbated by strongyloidiasis

DOI: 10.17235/reed.2022.9044/2022

Letter

Upadacitinib in refractory ulcerative colitis

DOI: 10.17235/reed.2022.8870/2022

Letter

Intestinal disease secondary to tocilizumab

DOI: 10.17235/reed.2022.8818/2022

Review

Clinical settings with tofacitinib in ulcerative colitis

DOI: 10.17235/reed.2022.8660/2022

Letter

NSAID-induced ischemic colitis

DOI: 10.17235/reed.2022.8605/2022

Letter

Mesalazine induced interstitial pneumonitis in the COVID era

DOI: 10.17235/reed.2022.8635/2021

Digestive Diseases Image

Portal pneumatosis in a patient with severe Salmonella colitis

DOI: 10.17235/reed.2021.8090/2021

Digestive Diseases Image

Phlebosclerotic colitis: an unusual cause of abdominal pain and hematochezia

DOI: 10.17235/reed.2020.7358/2020

Letter

The effect of Adacolumn® on ulcerative colitis with COVID-19

DOI: 10.17235/reed.2020.7156/2020

Rapid reviews

COVID-19, coronavirus, SARS-CoV-2 and the small bowel

DOI: 10.17235/reed.2020.7137/2020

Letter

Sweet syndrome in severe ulcerative flare

DOI: 10.17235/reed.2020.6995/2020

Digestive Diseases Image

Immune mediated colitis caused by lung cancer treatment with atezolizumab

DOI: 10.17235/reed.2017.5060/2017

Letter to the Editor

Cytomegalovirus: associated ischemic colitis in an immunocompetent patient

DOI: 10.17235/reed.2017.4937/2017

Letter to the Editor

Ulcerative colitis with gastric and duodenal involvement

DOI: 10.17235/reed.2017.4685/2016

Editorial

Specialist care in the management of inflammatory bowel disease

DOI: 10.17235/reed.2016.4628/2016

Original

Mercaptopurine and inflammatory bowel disease: the other thiopurine

DOI: 10.17235/reed.2016.4546/2016

Letter to the Editor

Ischemic colitis in an athlete: running is not always good for you

DOI: 10.17235/reed.2016.4184/2015

Case Report

Mesalamine-induced myopericarditis - A case report

DOI: 10.17235/reed.2016.4016/2015

Digestive Diseases Image

Fatal Campylobacter jejuni ileocolitis

Case Report

Severe ischemic colitis following olanzapine use - A case report

DOI: 10.17235/reed.2016.3944/2015

Case Report

Olanzapine-induced ischemic colitis

DOI: 10.17235/reed.2015.3856/2015

Citation tools
Salmón Olavarría P, Rubio Iturria S, Nantes Castillejo Ó. Tofacitinib, a useful option for the treatment of pyoderma gangrenosum in an ulcerative colitis patient. 7977/2021


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1867 visits.
This article has been downloaded 196 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 16/03/2021

Accepted: 26/03/2021

Online First: 13/04/2021

Published: 06/10/2021

Article revision time: 7 days

Article Online First time: 28 days

Article editing time: 204 days


Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2024 y Creative Commons. The Spanish Journal of Gastroenterology